AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8063021
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg acyclovir twice daily (first year)
Trial: 8063021
Drug: Open-label acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label acyclovir suppressive therapy (after first year)
Trial: 8063021
Drug: Suppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppressive therapy for 5 years
Trial: 31286397
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose of 1 μg kg-1 followed by 0.5 μg kg-1 h-1)
Trial: 31286397
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate (bolus 0.08 mg kg-1 followed by a saline infusion)
Trial: 31286397
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of intraoperative morphine consumption
Trial: 22517036
Drug: Higher parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher parenteral amino acid intakes (4 g kg(‐1) per day)
Trial: 22517036
Drug: Standard parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard parenteral amino acid intakes (3 g kg(‐1) per day)
Trial: 12582020
Drug: High-dose aliretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aliretinoin (50 mg)
Trial: 12582020
Drug: Low-dose aliretinoin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aliretinoin (25 mg)
Trial: 9171752
Drug: High-dose bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bolus tPA (three doses of 5 mg over 30 min, then 3.5 mg/h for up to 4 h, then 0.5-1.0 mg/h)
Trial: 9171752
Drug: Low-dose tPA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tPA (0.5-1.0 mg/h)
Trial: 3203706
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg benazepril
Trial: 3511937
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg acute treatment)
Trial: 3511937
Drug: Indomethacin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25 mg twice daily for 7 days chronic treatment)
Trial: 3511937
Drug: Indomethacin (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (acute and chronic treatments)
Trial: 29705457
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 5% lavender essential oil (2 drops)
Trial: 27206122
Drug: Renin angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin angiotensin system antagonists (RASA)
Trial: 27206122
Drug: All medication
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All medication classes combined
Trial: 24646861
Drug: PA21 (sucroferric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA21 (sucroferric oxyhydroxide) 1.0-3.0 g per day
Trial: 24646861
Drug: Sevelamer carbonate
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer carbonate 4.8-14.4 g per day
Trial: 24646861
Drug: PA21 maintenance
RxNorm normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PA21 maintenance dose
Trial: 24646861
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (250 mg per day)
Trial: 22226343
Drug: Inhaled loxapine
RxNorm normalized name: loxapine Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled loxapine 5 mg
Trial: 22226343
Drug: Inhaled loxapine
RxNorm normalized name: loxapine Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled loxapine 10 mg
Trial: 20578931
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (OROS MPH) 54 mg or greater
Trial: 20578931
Drug: Weight-adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-adjusted dose of OROS MPH
Trial: 20578931
Drug: Absolute dose
RxNorm normalized name: Honey Absolute
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absolute dose of OROS MPH
Trial: 12698305
Drug: Retigabine (RGB)
RxNorm normalized name: retigabine
DrugBank: Ezogabine (DB04953)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Retigabine (RGB) 200 mg single oral doses on day 1 and day 7, and Lamotrigine (LTG) 25 mg o.i.d. on days 3-8
Trial: 12698305
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) 200 mg single oral doses on day 1 and day 17, and up-titrated to 300 mg RGB b.i.d. on days 6-20
Trial: 1745707
Drug: Caffeine (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (1, 2, 3, and 4 mg/kg body weight)
Trial: 26606271
Drug: 1.5 g·kg⁻¹·h⁻¹
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g·kg⁻¹·h⁻¹ glucose (GLU)
Trial: 26606271
Drug: 1.2 g·kg⁻¹·h⁻¹
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g·kg⁻¹·h⁻¹ glucose + 0.3 g·kg⁻¹·h⁻¹ fructose (GLU + FRU)
Trial: 26606271
Drug: 0.9 g·kg⁻¹·h⁻¹
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 g·kg⁻¹·h⁻¹ glucose + 0.6 g·kg⁻¹·h⁻¹ sucrose (GLU + SUC)
Trial: 18277739
Drug: Oral-B CrossAction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B CrossAction manual toothbrush + Crest Pro-Health dentifrice (0.454% stannous fluoride/sodium hexametaphosphate)
Trial: 18277739
Drug: Oral-B ProfessionalCare
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B ProfessionalCare Series 8000 power toothbrush + Pro-Health dentifrice
Trial: 18277739
Drug: ProfessionalCare power
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProfessionalCare power brush + Pro-Health dentifrice + Oral-B Hummingbird power flosser
Trial: 10577995
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 4 mg, 8 mg, 16 mg
Trial: 12660683
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (all doses)
Trial: 8767620
Drug: defibrotide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: defibrotide (400 mg bid)
Trial: 8767620
Drug: heparan-sulfate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparan-sulfate (40 mg bid)
Trial: 7036914
Drug: Potassium supplements
RxNorm normalized name: POTASSIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium supplements (group A, n = 10)
Trial: 26502850
Drug: Capecitabine maintenance
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine maintenance therapy (oral capecitabine 1,250 mg/m2 twice daily on days 1-14 every 3 weeks)
Trial: 23081843
Drug: Gentamicin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (10 mg) added to contrast medium
Trial: 22919877
Drug: Intravenous pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pantoprazole (PPI) 80 mg + 8 mg/h for 72 hours
Trial: 11094036
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of [(3)H]L-arginine (100 nCi/min)
Trial: 11094036
Drug: [(3)H]L-arginine uptake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [(3)H]L-arginine uptake by peripheral blood mononuclear cells (PBMCs)
Trial: 1618242
Drug: Sustained-release nicardipine
RxNorm normalized name: nicardipine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release nicardipine 45-60 mg/d
Trial: 16395953
Drug: Antidepressant drug
RxNorm normalized name: MAO A Inhibitors, antidepressant drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant drug treatment
Trial: 17929555
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) and aspirin; n = 20
Trial: 17929555
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without GH or aspirin; n = 20
Trial: 12131260
Drug: 20 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g/d bovine colostrum + 40 g whey protein concentrate (wpc)
Trial: 9204351
Drug: iopentol 300
RxNorm normalized name: iopentol 300 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopentol 300 mg I/ml
Trial: 31290747
Drug: 1-day intravenous
RxNorm normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-day intravenous antibiotics (cefmetazole and metronidazole)
Trial: 31290747
Drug: 4-day intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day intravenous and oral antibiotics (cefmetazole and metronidazole)
Trial: 31290747
Drug: 1-day intravenous
RxNorm normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-day intravenous antibiotics
Trial: 31290747
Drug: 4-day intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day intravenous and oral antibiotics
Trial: 23471413
Drug: JNJ‐39588146 (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐39588146 (any dose)
Trial: 20803860
Drug: 0.5% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% levobupivacaine 7.5 mg (Group I)
Trial: 20803860
Drug: 0.5% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% levobupivacaine 10 mg (Group II)
Trial: 20803860
Drug: 0.5% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% levobupivacaine 12.5 mg (Group III)
Trial: 20803860
Drug: 0.5% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% levobupivacaine 15 mg (Group IV)
Trial: 7707407
Drug: Standard radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radiation therapy (60 Gy delivered at 2 Gy per fraction, 5 days a week, over a 6-week period)
Trial: 7707407
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (cisplatin 100 mg/m2 on days 1 and 29, vinblastine 5 mg/m2 per week for 5 weeks) followed by standard radiation therapy (starting on day 50)
Trial: 7707407
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy (69.6 Gy delivered at 1.2 Gy per fraction twice daily)
Trial: 25351561
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of daidzein
Trial: 25351561
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of genistein
Trial: 25351561
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of soy protein plus no addition
Trial: 9062602
Drug: Pethidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (0.1 ml, 10 mg/ml) combined with lidocaine (3 ml, 2%)
Trial: 9062602
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.1 ml) combined with lidocaine (3 ml, 2%)
Trial: 22734388
Drug: Combined Therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Therapy (Acupotomy + Blood Pricking)
Trial: 20668051
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1500 mg Ca/d from 20 weeks of gestation until delivery)
Trial: 18346640
Drug: anti-CD25 monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-CD25 monoclonal antibody (Daclizumab)
Trial: 11956046
Drug: Salbutamol 100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 100, 100, and 200 microg inhaled at 5-minute intervals after exercise
Trial: 7636536
Drug: Dexverapamil 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexverapamil 120 mg/m2 plus vinblastine 0.11 mg/kg IV on days 1 and 2 every 21 days
Trial: 7636536
Drug: Dexverapamil 180
RxNorm normalized name: verapamil hydrochloride 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexverapamil 180 mg/m2 plus dexamethasone plus vinblastine 0.11 mg/kg IV on days 1 and 2 every 21 days
Trial: 326013
Drug: 1 Gm.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Gm. of ASA daily
Trial: 26536443
Drug: Preoperative cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative cognitive-behavioral therapy (CBT)
Trial: 24308723
Drug: Long-acting testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting testosterone undecanoate (TU) 1,000 mg
Trial: 23346766
Drug: Group IV
RxNorm normalized name: Corticosteroids, very potent (group IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group IV (20 ml dexamethasone at 0.5 mg/ml, injected over 30s)
Trial: 23346766
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (2 ml dexamethasone at 5 mg/ml, injected over 5s)
Trial: 23346766
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (4 ml dexamethasone at 2.5 mg/ml, injected over 5s)
Trial: 23346766
Drug: Group III
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III (10 ml dexamethasone at 1 mg/ml, injected over 5s)
Trial: 20516633
Drug: Etidronate (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (20 mg/kg/day for 12 weeks)
Trial: 20516633
Drug: Indomethacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (75 mg/day for 2 weeks)
Trial: 18612156
Drug: Capecitabine as
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine as second treatment (1,250 mg/m² twice daily, days 1 through 14)
Trial: 18612156
Drug: Capecitabine as
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine as first treatment (1,250 mg/m² twice daily, days 1 through 14)
Trial: 18612156
Drug: FU/LV as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FU/LV as first treatment (425 mg/m² FU, 45 mg LV, once weekly for 6 weeks)
Trial: 18612156
Drug: FU/LV as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FU/LV as second treatment (425 mg/m² FU, 45 mg LV, once weekly for 6 weeks)
Trial: 6313458
Drug: Cimetidine, 200
RxNorm normalized name: Cimetidine, 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 200 mg three times a day and 400 mg at night
Trial: 29208190
Drug: Three-session, manualised,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-session, manualised, psychosocial, gender-specific group intervention plus BBV transmission information booklet and treatment as usual (TAU)
Trial: 22565002
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/d plus Everolimus 10 mg/d
Trial: 22565002
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/d alone
Trial: 17469692
Drug: Cholinesterase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitors (especially donepezil)
Trial: 17469692
Drug: NMDA receptor
RxNorm normalized name: NMDA receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMDA receptor antagonist (memantine)
Trial: 16035127
Drug: Timed bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timed bright light therapy (morning or afternoon exposure at > or = 2500 lux)
Trial: 11831542
Drug: Oxycodone 5
RxNorm normalized name: oxycodone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 5 mg/325 mg
Trial: 11831542
Drug: Oxycodone 7.5
RxNorm normalized name: oxyCODONE 7.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 7.5 mg/500 mg
Trial: 11831542
Drug: Oxycodone 10
RxNorm normalized name: oxycodone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 10 mg/650 mg
Trial: 2188165
Drug: Sublingual captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual captopril (SLC) 25 mg
Trial: 2188165
Drug: Sublingual nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual nifedipine (SLN) 10 mg
Trial: 18827360
Drug: Extended-release (ER)
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release (ER) formulations of glipizide (fast, moderate, slow)
Trial: 18827360
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) formulation of glipizide
Trial: 10688396
Drug: Etanercept 10
RxNorm normalized name: Etanercept 10 mg powder for solution for injection vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 10 mg
Trial: 8325622
Drug: Terlipressin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (2 mg and then 1 mg/4 hr over 24 hr) and transdermal nitroglycerin (10 mg/12 hr over 24 hr)
Trial: 8325622
Drug: Octreotide (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (continuous intravenous infusion of 25 micrograms/hr over 12 hr and then 100 micrograms at hr 12 and hr 18 subcutaneously)
Trial: 27807890
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg extended-release aspirin
Trial: 24375476
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic application for 30 minutes
Trial: 24375476
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic application for 60 minutes
Trial: 24375476
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic application for 30 minutes vs 60 minutes
Trial: 23250175
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of preprocedural mouthrinsing with 0.2% chlorhexidine gluconate and high volume evacuator attachment
Trial: 12068251
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg ethanol
Trial: 11602546
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg daily for 3 months)
Trial: 7938398
Drug: Sublingual captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual captopril
Trial: 27617366
Drug: One of
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One of four text versions of a warning label (e.g., SAFETY WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay)
Trial: 24899156
Drug: Fresh avocado
RxNorm normalized name: Avocado
DrugBank: Avocado (DB10504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh avocado (23 g of lipid) with high-β-carotene tomato sauce (33.7 mg of β-carotene)
Trial: 24899156
Drug: Fresh avocado
RxNorm normalized name: Avocado
DrugBank: Avocado (DB10504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh avocado (23 g of lipid) with raw carrots (27.3 mg of β-carotene and 18.7 mg of α-carotene)
Trial: 24899156
Drug: Fresh avocado
RxNorm normalized name: Avocado
DrugBank: Avocado (DB10504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh avocado (23 g of lipid)
Trial: 15935646
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: CI 10 mL/h, PCEA bolus 6 mL, 8‐min lockout
Trial: 15935646
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: CI 10 mL/h, PCEA bolus 12 mL, 16‐min lockout
Trial: 15935646
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: CI 15 mL/h, PCEA bolus 6 mL, 8‐min lockout
Trial: 15935646
Drug: Group D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D: CI 15 mL/h, PCEA bolus 12 mL, 16‐min lockout
Trial: 8988070
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide (2 mg twice daily)
Trial: 8988070
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (30 mg once daily)
Trial: 29878869
Drug: 400 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 µg salbutamol administered before exercise
Trial: 27559041
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg loading dose / 10 mg maintenance dose once daily)
Trial: 27559041
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg loading dose / 90 mg maintenance dose twice daily)